Spero Therapeutics (SPRO) Other Accumulated Expenses (2016 - 2026)

Spero Therapeutics has reported Other Accumulated Expenses for 11 years, with the latest figure at $75000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 26.47% year-over-year to $75000.0; the trailing twelve-month figure through Mar 2026 stood at $75000.0 (down 26.47% YoY), and the FY2025 full-year result was $133000.0, up 10.83% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $75000.0, down from $133000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $1.2 million in Q3 2023, with the low at $75000.0 in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $286882.4 across 5 years, with a median of $171000.0 in 2023.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses soared 468.25% — and 2024, when it plunged 84.15%.
• Spero Therapeutics' Other Accumulated Expenses stood at $209000.0 in 2022, then gained by 12.92% to $236000.0 in 2023, then plunged by 49.15% to $120000.0 in 2024, then rose by 10.83% to $133000.0 in 2025, then sank by 43.61% to $75000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $75000.0 (Q1 2026), $133000.0 (Q4 2025), and $82000.0 (Q3 2025), per Business Quant data.